1. Finland Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Orion Oyj

Orion Oyj

ORINY
Orion OyjUS flagOther OTC
51.10
USD
+4.45
- -
28.69BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3.57
3.61
3.61
3.82
3.68
3.47
3.74
3.84
3.7
4.77
4.24
5.49
6.72
5.96
Basic EPS, GAAP
0.73
0.75
0.74
0.89
0.8
1.17
0.71
0.78
0.69
1.24
0.77
1.17
1.78
1.34
Free Cash Flow per Basic Share
0.5
0.85
0.75
0.71
0.54
0.58
0.83
0.92
0.46
1.29
0.01
0.73
0.78
0.77
Dividend per Share
0.65
0.63
0.65
0.65
0.78
0.72
0.75
0.75
0.75
0.75
0.8
0.81
0.82
0.82
Book Value per Share
3.66
3.66
4.22
4.57
4.83
5.49
5.55
5.21
5.32
6.48
6.34
7.15
9.13
6.54
Tangible Book Value per Share
3.15
3.2
3.81
4.18
4.46
5.04
5.18
4.9
4.83
5.12
4.92
5.91
7.8
5.21
Basic Weighted Avg Shares
282
281
282
281
281
281
281
281
281
281
281
281
281
281
Sales/Revenue/Turnover
1,007
1,015
1,016
1,074
1,034
978
1,051
1,078
1,041
1,341
1,190
1,542
1,890
1,677
Operating Margin (%)
26.27
26.75
26.36
27.22
27.44
25.69
23.94
25.64
22.83
32.54
22.29
26.88
33.29
28.46
Depreciation Expense
38
40
42
41
42
42
56
56
46
48
52
93
57
- -
Net Income, GAAP
206
211
208
249
226
330
200
220
194
350
217
330
500
378
Effective Tax Rate (%)
21.89
21.14
20.66
19.91
21.1
20.53
20.14
20.98
20.02
20.62
20.26
20.14
20.31
20.18
Profit Margin (%)
20.48
20.81
20.5
23.19
21.87
33.79
19.07
20.4
18.62
26.07
18.22
21.39
26.48
22.54
Working Capital
432
438
441
461
441
414
412
530
481
603
561
742
784
467
LT Debt
233
210
178
150
150
1
7
106
105
197
171
297
115
136
Total Equity
514
515
595
641
680
773
779
731
748
908
890
1,005
1,284
920
Return on Invested Capital (%)
28.94
28.11
27.68
29.49
27.33
22.6
23.26
26.58
22.16
34.67
18.9
26.92
33.32
33.47
Return on Capital (%)
29.53
28.35
27.72
32.05
28.25
38.03
23.6
27.08
22.94
35.45
19.97
27.74
34.69
33.48
Return on Common Equity (%)
40.3
41.08
37.52
40.28
34.21
45.47
25.82
29.11
26.2
42.21
24.11
34.82
43.7
44.96

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
30
30
182
LT Borrowings
291
- -
- -
LT Finance Leases
6
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
141
141
141
Market Capitalization
2,978
3,899
4,438

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
1,016
1,084
1,008
Cash, Cash Equivalents & STI
206
259
184
Accounts Receivable, Net
255
288
252
Inventories
419
433
442
Total Current Liabilities
274
278
541
Payables & Accruals
- -
- -
- -
ST Debt
30
30
182
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.46%
12.49%
27.81%
Free Cash Flow
935.18%
1,864.03%
6.15%
Net Income, GAAP
16.12%
26.86%
51.65%
Sales/Revenue/Turnover
7.29%
13.25%
22.5%
Total Cash Common Dividend
- -
- -
1.36%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
308
328
471
434
1,542
2025
355
416
695
- -
1,890
2026
418
522
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.16
0.19
0.57
0.26
1.17
2025
0.22
0.29
0.92
- -
1.78
2026
0.32
0.5
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.4
- -
0.4
0.81
2025
- -
0.41
0.41
- -
0.82
2026
- -
0.45
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Aino Anna Liisa Hurme
Full Time Employees
4,029
Sector
Healthcare
Industry
Drug Manufacturers - General
Address
Orionintie 1A Espoo UU Finland 02200
IPO Date
Dec 9, 2014
Website
orionpharma.com
Similar Companies
Orion Oyj (ORINY)
Horizon Therapeutics Public Limited Company (HZNP)
Bayer AG (BAYRY)
BioDelivery Sciences Intl, Inc. Wrrt (BDSIW)
Marksans Pharma Limited (MARKSANS.NS)
CSPC Pharmaceutical Group Limited (CSPCY)
Business
Orion Oyj, a globally operating Finnish pharmaceutical company founded in 1917 and headquartered in Espoo, Finland, develops, manufactures and markets human pharmaceuticals, veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) for global markets, with all manufacturing sites and most R&D units located in Finland. The company's human pharmaceutical portfolio includes proprietary branded products such as Nubeqa for prostate cancer treatment; Entacapone, Stalevo, Comtess and Comtan for Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Trexan for rheumatoid arthritis and cancer; and Dexdor, Precedex and Dexmedetomidine for sedation and intensive care, alongside generic drugs, self-care products including non-prescription medicines and vitamins, and diagnostic tests; its veterinary offerings cover pain management, sedation, joint and mobility support, behavioral balance, gastrointestinal balance, eye and ear care, dental care, skin and fur treatments, and health recovery products for companion animals and livestock; through its subsidiary Fermion, Orion produces APIs for internal use and external contract manufacturing customers worldwide. Orion focuses R&D on core therapeutic areas including oncology, neurological disorders such as Parkinson's and insomnia, pain management, respiratory diseases and inhaled pulmonary medications, serving specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics and laboratories across international markets with primary operations in Europe, North America and other regions. Recent developments include an exclusive commercial license agreement in October 2025 with Abzena for a monoclonal antibody targeting a high unmet-need cancer, strengthening Orion's oncology pipeline; a EUR 180 million milestone payment received in December 2025 related to Nubeqa sales, accompanied by an updated full-year 2025 outlook; the phase 2 study of ODM-105 for insomnia not meeting its primary goal in September 2025; multiple share conversions from A to B shares throughout 2025 including 71,498 shares in November and 49,164 in October; and receipt of the President of Finland's international growth award in November 2025.

Company News

Company News APIChatGPT

  • defenseworld.net

    Orion OYJ (OTCMKTS:ORINY) & Sonoma Pharmaceuticals (NASDAQ:SNOA) Head to Head Contrast

  • defenseworld.net

    Orion OYJ (OTCMKTS:ORINY) Shares Gap Down – Here’s What Happened

  • defenseworld.net

    Financial Analysis: Orion OYJ (OTCMKTS:ORINY) versus Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY)

  • defenseworld.net

    Orion OYJ (OTCMKTS:ORINY) Hits New 52-Week High – Time to Buy?

  • seekingalpha.com

    Orion Oyj (ORINF) Q1 2026 Earnings Call Transcript

  • seekingalpha.com

    Orion Oyj (ORINF) Q4 2025 Earnings Call Transcript

  • globenewswire.com

    Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

  • seekingalpha.com

    Orion Oyj (ORINF) Q3 2025 Earnings Call Transcript

  • zacks.com

    What Makes Orion OYJ (ORINY) a Good Fit for 'Trend Investing'

  • zacks.com

    5 Stocks With Recent Price Strength to Maximize Your Gains

  • zacks.com

    Here is Why Growth Investors Should Buy Orion OYJ (ORINY) Now

  • zacks.com

    Orion OYJ (ORINY) is on the Move, Here's Why the Trend Could be Sustainable

  • seekingalpha.com

    Orion Oyj (ORINF) Q2 2025 Earnings Call Transcript

  • zacks.com

    Looking for a Growth Stock? 3 Reasons Why Orion OYJ (ORINY) is a Solid Choice

  • zacks.com

    Recent Price Trend in Orion OYJ (ORINY) is Your Friend, Here's Why

  • seekingalpha.com

    ORION Holdings Corp. (ORINF) Q1 2025 Earnings Call Transcript

  • zacks.com

    Orion OYJ (ORINY) Is a Great Choice for 'Trend' Investors, Here's Why

  • zacks.com

    Is Orion OYJ (ORINY) a Solid Growth Stock? 3 Reasons to Think "Yes"

  • seekingalpha.com

    Orion Oyj (ORINF) Q4 2023 Earnings Call Transcript